CAR-T细胞治疗后噬血细胞性淋巴组织细胞增多症的系统综述与荟萃分析
汇总HLH发生率为1.6%(中位随访12.9个月),HLH相关死亡率为0.7%。HLH风险主要取决于基础疾病类型和CAR-T产品,B-ALL及Tisa-cel、Cilta-cel使用者风险最高。
要点
- CAR-T后HLH汇总发生率1.6%,HLH相关死亡率0.7%。
- B-ALL患者HLH发生率最高(6.9%),Tisa-cel产品发生率最高(4.3%)。
- 高级别CRS与HLH发生率正相关,尤其在多发性骨髓瘤中。
核心结论
- CAR-T治疗后HLH风险主要由基础疾病类型和特定CAR-T产品驱动,严重CRS亦有贡献。
- 总体HLH发生率与死亡率呈显著正相关。
- 建议对高危群体(尤其B-ALL患者及Tisa-cel或Cilta-cel接受者)加强监测和早期干预。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane CENTRAL至2025年8月20日。
主要发现
- 汇总HLH发生率为1.6%,中位随访12.9个月,HLH相关死亡率为0.7%。
- HLH发生率因疾病实体不同而差异显著(p=0.0008),B-ALL最高(6.9%)。
- CAR-T产品是显著决定因素(p=0.0036),Tisa-cel发生率最高(4.3%)。
- 在大B细胞淋巴瘤中,Tisa-cel的HLH发生率显著高于Axi-cel(2.4% vs. 0.6%,p=0.038)。
- 在多发性骨髓瘤中,Cilta-cel的HLH发生率高于Ide-cel(2.6% vs. 0.7%,p=0.022)。
关键数值与推荐
- HLH汇总发生率1.6%,HLH相关死亡率0.7%。
- B-ALL中HLH发生率为6.9%,Tisa-cel产品为4.3%。
- 大B细胞淋巴瘤中Tisa-cel vs. Axi-cel的HLH发生率为2.4% vs. 0.6%(p=0.038)。
- 多发性骨髓瘤中Cilta-cel vs. Ide-cel的HLH发生率为2.6% vs. 0.7%(p=0.022)。
临床怎么用
- 对接受CAR-T治疗的高危患者(B-ALL、使用Tisa-cel或Cilta-cel)应加强HLH监测。
- 出现高级别CRS时需警惕HLH发生,尤其在多发性骨髓瘤患者中。
- 早期识别和干预HLH可能降低HLH相关死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric Antigen Receptor T-cell Immunotherapy represents a breakthrough in treating relapsed/refractory hematologic malignancies, yet immune-related adverse events, particularly hemophagocytic lymphohistiocytosis (HLH), also known as immune effector cell-associated HLH-like syndrome (IEC-HS), are rapid-progressing and life-threatening. This systematic review and meta-analysis searched PubMed, Embase, and Cochrane CENTRAL up to August 20, 2025. Nineteen studies were analyzed using a random-effects model, covering 2780 patients, 47 HLH cases, and 20 HLH-related deaths. The pooled incidence of HLH was 1.6% at a median follow-up of 12.9 months, with an associated HLH mortality of 0.7%. The incidence of HLH differed markedly by disease entity (p = 0.0008), highest in B-cell acute lymphoblastic leukemia (B-ALL: 6.9%). CAR T-cell product was also a significant determinant (p = 0.0036), with tisagenlecleucel (Tisa-cel) showing the highest incidence (4.3%). Subgroup analyses confirmed that Tisa-cel had a significantly higher HLH incidence than axicabtagene ciloleucel (Axi-cel) in large B-cell lymphoma (2.4% vs. 0.6%, p = 0.038), and ciltacabtagene autoleucel (Cilta-cel) had a higher incidence than idecabtagene vicleucel (Ide-cel) in multiple myeloma (2.6% vs. 0.7%, p = 0.022). Higher-grade cytokine release syndrome (CRS) was positively correlated with HLH incidence, particularly in MM. Overall HLH incidence was significantly positively correlated with mortality. In conclusion, HLH risk after CAR T-cell therapy is primarily driven by underlying disease type and specific CAR T-cell product, with additional contribution from severe CRS. Enhanced surveillance and early intervention are strongly recommended for high-risk groups, particularly B-ALL patients and recipients of Tisa-cel or Cilta-cel.
引用
- Zhang C, Wu H, Cao T, et al. Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis. Am J Hematol. 2026. PMID: 42086512. doi:10.1002/ajh.70351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。